Testing the Addition of an Anti-cancer Drug, Berzosertib, to the Usual Treatment (Radiation Therapy) for Chemotherapy-Resistant Triple-Negative and Estrogen and/or Progesterone Receptor Positive, HER2 Negative Breast Cancer
Summary
The registered summary isn't in our current data snapshot. Read it on the ClinicalTrials.gov record ↗. Why? →
Investigators
The overall officials registered on this study. Names that resolve to a findmyKOL profile link to it; the rest are shown as registered.
- Robert W Mutter
Dana-Farber - Harvard Cancer Center LAO
Principal Investigator
A profile link is shown only when the registered name resolves to a person record with a confident, namesake-checked match; ambiguous names stay unlinked.
Sites
14 registered facilities, with the per-site recruitment status where the registry publishes one. ClinicalTrials.gov does not publish per-site enrollment counts.
- Mayo Clinic Hospital in Arizona
Phoenix, Arizona, United States
- Mayo Clinic in Arizona
Scottsdale, Arizona, United States
- University of California Davis Comprehensive Cancer Center
Sacramento, California, United States
- Mayo Clinic in Florida
Jacksonville, Florida, United States
- Mayo Clinic in Rochester
Rochester, Minnesota, United States
- Rutgers Cancer Institute of New Jersey
New Brunswick, New Jersey, United States
- Nyp/weill Cornell Medical Center
New York, New York, United States
- Ohio State University Comprehensive Cancer Center
Columbus, Ohio, United States
- University of Pittsburgh Cancer Institute (upci)
Pittsburgh, Pennsylvania, United States
- University of Texas Medical Branch
Galveston, Texas, United States
- Farmington Health Center
Farmington, Utah, United States
- Huntsman Cancer Institute/university of Utah
Salt Lake City, Utah, United States
- University of Utah Sugarhouse Health Center
Salt Lake City, Utah, United States
- University of Wisconsin Carbone Cancer Center - University Hospital
Madison, Wisconsin, United States
Site investigator names are published by ClinicalTrials.gov only while a study recruits, so completed studies list sites without them.
Drugs studied
No drug or biological interventions are in our data for this study — it may test a procedure, device or behavioral intervention, or the intervention list isn't in our current snapshot. See the registry record ↗. Why? →
Registration & key dates
Registry attributes as recorded on the ClinicalTrials.gov study record.
- Start
- 24 Sept 2020
- Primary completion
- 24 Feb 2027
- Completion
- 24 Feb 2027
- Last update posted
- 13 May 2026
- Registered enrollment
- 42
- Registry id
- NCT04052555
Source: ClinicalTrials.gov, via the CTTI AACT database, data as of 12 Jul 2026. Registry facts are shown as registered by the study sponsor; findmyKOL does not interpret them.